Nintedanib Combined with Docetaxel or
Pemetrexed Enhances Antitumour Efficacy
• Combination of suboptimal doses of nintedanib and docetaxel or pemetrexed results in
improved
antitumour efficacy
compared with single-agent treatments and is
well tolerated
15
NCI-H460 xenograft
Calu-6 xenograft
0
200
400
600
800
1000
1200
1400
1600
1800
13
15
17
19
21
23
25
27
29
31
33
35
Days
Tumour volume [mm³]
Nintedanib, 25mg/kg, qd, p.os
Docetaxel, 7.5mg/kg q7d, i.v
Nintedanib + Docetaxel
T/C
60%
69%
24%
Control
0,0
100,0
200,0
300,0
400,0
500,0
600,0
700,0
800,0
900,0
1000,0
0
5
10
15
20
25
30
Days
Tumour volume [mm³]
Control 125mg/kg, q7d,
64%
41%
24%
Pemetrexed i.p
Nintedanib + pemetrexed
Nintedanib, 50 mg/kg, qd
T/C
Hilberg F, J Thoracic Oncol 2007
